BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview


2024/10/18 22:00	:01	
Price 8.16 USD		
Difference	0	-2.39% (-0.20)

General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	NYSE			
Currency	USD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,766 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.10 USD (1,100)
Ask (Ask size)	8.30 USD (100)
Open	8.22 USD
High	8.28 USD
Low	8.07 USD
Close (prev. day)	8.36 USD
VWAP	8.156347 USD
Volume (pcs)	1,481,373
Trading volume	12,082,417.94
Number of trades	10,881
Last size	-

Futures and Options	
Related Futures	14
Related Options	-

PDF Downloads	
Company report: BAUSCH HEALTH	
COMPANIES INC.	



Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

on sector			
Date		Headline	Download
2024/09/27	80 28 82 188	Global Equity Ratings	
2024/09/11	8. [28 27] [8]	Global Equity Ratings	
2024/09/05	8. 28 27 18	Global Equity Ratings	
2024/08/12	84 (2) 21 (8)	Global Equity Ratings	
2024/07/24	8. 28 27 18	Global Equity Ratings	




Details

2024/10/18 22:00:01				
Price				
8.16 USD				
Difference	0	-2.39% (-0.20)		

General attributes				
ISIN	CA0717341071			
Symbol	BHC			
Exchange	NYSE			
Currency	USD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,766 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.10 USD (1,100)
Ask (Ask size)	8.30 USD (100)
Open	8.22 USD
High	8.28 USD
Low	8.07 USD
Close (prev. day)	8.36 USD
VWAP	8.156347 USD
Volume (pcs)	1,481,373
Trading volume	12,082,417.94
Number of trades	10,881
Last size	_

Performance and Risk					
	6m	1Y	3Y		
Perf (%)	-5.12%	+5.15%	-70.93%		
Perf (abs.)	-0.44	+0.40	-19.91		
Beta	1.37	1.69	1.77		
Volatility	56.75	49.16	70.56		



Information about previous performance does not guarantee future performance. $\textbf{Source:} \ \ \textbf{FactSet}$

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	8.32 USD (2,077,974)
Ø price 30 days Ø volume 30 days (pcs.)	7.78 USD (2,176,735)
Ø price 100 days Ø volume 100 days (pcs.)	6.79 USD (3,087,370)
Ø price 250 days Ø volume 250 days (pcs.)	7.56 USD (2,817,022)
YTD High date	11.46 USD (2024/04/03)
YTD Low date	3.96 USD (2024/07/24)
52 Weeks High date	11.46 USD (2024/04/03)
52 Weeks Low date	3.96 USD (2024/07/24)

Arbitrage views					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/10/ 18	22:02	7.516 EUR	0.00	1
Toronto Stock Exchange	2024/10/ 18	22:00	11.26 CAD	2.54	1,057
Stuttgart	2024/10/ 18	21:31	7.492 EUR	0.00	5
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/10/	22:00	8.16 USD	12.08	10,881



	18				
Munich	2024/10/ 18	08:01	7.52 EUR	0.00	2
Frankfurt	2024/10/ 18	08:16	7.361 EUR	0.00	2
Duesseldorf	2024/10/ 18	08:10	7.359 EUR	0.00	3
Berlin	2024/10/ 18	08:01	7.361 EUR	0.00	2



Company profile

Company Logo

BAUSCH Health

Contact Details

BAUSCH HEALTH COS. INC.

_ _

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Mellibers of M	Wellibers of Management Board			
Thomas Appio	Chairman of Managing Board			
Tage Ramakrishna	Member of Executive Committee			
Cees Heiman	Member of Executive Committee			
Fernando Zarate	Member of Executive Committee			
Graham Jackson	Member of Executive Committee			
Jeff Hartness	Member of Executive Committee			
Kathleen Fitzpatrick	Member of Executive Committee			
Mirza Dautbegovic	Member of Executive Committee			

Member of Executive

Member of Executive

Committee

Committee

Seana Carson

Tom Vadaketh

Members of Management Roard

æ,

Board of directors		
John Paulson	Chairman of Supervisory Board	
Amy Wechsler	Member of Supervisory Board	
Richard Mulligan	Member of Supervisory Board	
Brett Icahn	Member of Supervisory Board	
Christian Garcia	Member of Supervisory Board	
Frank Lee	Member of Supervisory Board	
Robert Power	Member of Supervisory Board	
Sarah Kavanagh	Member of Supervisory Board	
Steven Miller	Member of Supervisory Board	

